Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma
Conditions
Keywords
MB-CART19.1 Cellular Therapy, Relapsed/Refractory, CliniMACS Prodigy Device
Brief summary
This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Interventions
BIOLOGICALMB-CART19.1 Cellular Therapy
MB-CART19.1 will be infused as a single infusion during an inpatient admission.
Sponsors
Memorial Sloan Kettering Cancer Center
Miltenyi Biomedicine GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
It is modeled on a 3+3 design.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women who are at least 18 years of age on the day of consenting to the study. * Histologically documented primary or secondary central nervous system lymphoma of DLBCL subtype * Relapsed/refractory primary or secondary CNSL patients. All relapsed//refractory patients need to have received at least one prior CNS-directed methotrexate-based therapy. There is no restriction on the number of recurrences. * For relapsed patients, parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) within 21 days of study consent. * For refractory patients, there must be residual disease after their last line of therapy. * For patients with leptomeningeal disease only, CSF cytology and/or flow cytometry must document CSF findings consistent with CSF involvement by lymphoma and/or imaging findings consistent with CSF disease within 21 days of study registration (at the discretion of the investigator). * Creatinine Clearance ≥ 40 ml/min/m2, direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN) * Adequate pulmonary function as assessed by ≥90% oxygen saturation on room air by pulse oximetry. * Must be able to tolerate both MRI and CT scans * Must be able to tolerate lumbar puncture and/or Ommaya taps * Must have been either off corticosteroids, or on a stable or decreasing dose of dexamethasone equivalent ≤ 2 mg daily for 7 days before apheresis and 72 hours prior to CAR T cell infusion o Use of corticosteroids to treat CAR T cell toxicities per MSKCC guidelines is permitted
Exclusion criteria
* ECOG performance status \>2 o Patients with ECOG status of 2 will be enrolled at the discretion of the PI * Active systemic lymphoma (i.e. involvement outside of the CNS) * If the most recent CSF or brain tissue sample demonstrates absence of CD19 expression * Size of any single CNS lymphoma lesion exceeds 3 cm in maximal diameter in eloquent brain structures. * Prior treatment of systemic lymphoma with CD19-targeted CAR T cells * Pregnant or lactating patients. Patients of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished. * Impaired cardiac function (LVEF \<40%) as assessed by most recent ECHO in the last 1 year. * Patients with autoimmune disease requiring systemic T cell-suppressive therapy. * Patients with following cardiac conditions will be excluded: * New York Heart Association (NYHA) stage III or IV congestive heart failure * Myocardial infarction ≤6 months prior to enrollment * History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment * Patients with ocular lymphoma in the absence of other CNS involvement * Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy. * Patients with HIV * Patients with active hepatitis B or hepatitis C infection (as manifested by either detectable hepatitis B virus DNA by PCR, hepatitis virus C RNA by PCR, or positivity for hepatitis B surface or core antigen) * Patients with uncontrolled systemic fungal, bacterial, viral or other infection at time of leukapheresis or at time of CAR T cell infusion * Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin * Patients exposed to immune checkpoint inhibitor within 8 weeks * Use of herbal supplements are not allowed on study * Any other issue which, in the opinion of the treating physician or PI, would make the patient ineligible for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To identify the maximum tolerated dose (MTD) | 1 year | The maximum tolerated dose (MTD) is defined as the highest dose level where a Dose limiting toxicity (DLT) occurs within at most one out of six patients treated. DLT is defined as any of the following adverse events (AEs) that occur within 28 days of the MB-CART19.1 infusion, based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, TIAN grading65, or the ASTCT Consensus Grading guidelines for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS). |
Countries
United States
Contacts
CONTACTIvan Kotchetkov, MD
CONTACTMaria Palomba, MD
PRINCIPAL_INVESTIGATORIvan Kotchetkov, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed